BioCentury
ARTICLE | Company News

Immunexpress, Center for Translational Molecular Medicine infectious news

April 15, 2013 7:00 AM UTC

Immunexpress joined the Molecular Diagnosis and Risk Stratification of Sepsis (MARS) Consortium, a multicenter project aimed at developing and validating technologies for early diagnosis and prognosis of sepsis. The consortium was established by Center for Translational Molecular Medicine (CTMM) to improve clinical outcomes and reduce healthcare costs associated with sepsis. The project has a €14 million ($18.2 million) budget, with half coming from the Dutch government. The consortium is enrolling more than 7,000 patients at the University of Amsterdam and the University of Utrecht in a sepsis clinical trial. The CTMM has 119 partners, 22 projects/consortia and a €302.7 million ($393.1 million) budget allocated until the end of 2015. The CTMM is funded by the Dutch government (50%), academia (25%) and industry (25%), with additional funding provided by supporting foundations. ...